Retrospective Analysis of a Real-Life Use of Tixagevimab–Cilgavimab plus SARS-CoV-2 Antivirals for Treatment of COVID-19

Tixagevimab–cilgavimab is effective for the treatment of early COVID-19 in outpatients with risk factors for progression to severe illness, as well as for primary prevention and post-exposure prophylaxis. We aimed to retrospectively evaluate the hospital stay (expressed in days), prognosis, and nega...

Descripción completa

Detalles Bibliográficos
Autores principales: Capoluongo, Nicolina, Mascolo, Annamaria, Bernardi, Francesca Futura, Sarno, Marina, Mattera, Valentina, di Flumeri, Giusy, Pustorino, Bruno, Spaterella, Micaela, Trama, Ugo, Capuano, Annalisa, Perrella, Alessandro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10609705/
https://www.ncbi.nlm.nih.gov/pubmed/37895964
http://dx.doi.org/10.3390/ph16101493

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10609705/
https://www.ncbi.nlm.nih.gov/pubmed/37895964
http://dx.doi.org/10.3390/ph16101493

Ejemplares similares